EP0774009A1 - Procede de preparation de virus et de vecteurs viraux - Google Patents

Procede de preparation de virus et de vecteurs viraux

Info

Publication number
EP0774009A1
EP0774009A1 EP95926867A EP95926867A EP0774009A1 EP 0774009 A1 EP0774009 A1 EP 0774009A1 EP 95926867 A EP95926867 A EP 95926867A EP 95926867 A EP95926867 A EP 95926867A EP 0774009 A1 EP0774009 A1 EP 0774009A1
Authority
EP
European Patent Office
Prior art keywords
adenovirus
plasmid
dna
cells
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95926867A
Other languages
German (de)
English (en)
Inventor
Thomas von Rüden
Matthew Cotten
Ernst Wagner
Kurt Zatloukal
Heike Lehrmann
Birgit PANZENBÖCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP0774009A1 publication Critical patent/EP0774009A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the invention relates to the production of viruses and viral vectors, in particular with regard to uses in gene therapy.
  • Retroviral vectors are particularly characterized by a high infection efficiency and the stable integration of the provirus into the host cell genome. They thus enable stable gene transfer to most of the dividing primary cells.
  • the titer of recombinant retroviruses is usually still considerably lower (1 - 10 x 10 5 cfu / ml) and can often only be achieved after laborious cloning of virus-producing cells.
  • Relatively high titers can be obtained from small retroviral vectors that carry a single gene, eg N2 (Armentano et al., 1987), while the titers generally decrease with increasing vector size, eg when a second gene is transduced. It has been observed that the titers often correlate with the number of integrated virus copies.
  • the low titer is a major disadvantage, while the problem of limited packaging capacity is generally less of an issue, because in most cases cDNAs are expressed.
  • the packaging cell lines previously used are therefore obviously not suitable for gene transfer in vivo. In addition, this method is labor-intensive and time-consuming because the co-cultivation takes a long time and the cells then have to be cloned.
  • a new packaging cell line has recently been described which is derived from the Ad5-transformed human embryonic kidney cell line 293. This cell line allows the formation of high titers on retroviral vectors after transient transfection (Pear et al., 1993).
  • gene therapy applications include the paravovirus AAV ("adeno-associated virus", dependent on a helper virus), herpes viruses and adenoviruses were used (review by Jolly, 1994; Trapnell and Gorziglia, 1994).
  • paravovirus AAV adeno-associated virus
  • herpes viruses and adenoviruses were used (review by Jolly, 1994; Trapnell and Gorziglia, 1994).
  • the production of recombinant AAV virus usually starts with a transfection of vector DNA sequences.
  • the AAV vectors lack important replication functions and suitable packaging lines are not yet available, the production of AAV particles requires an infection with helper virus in addition to the transfection: the methods currently used for the production of recombinant AAV require a transfection in order to obtain a plasmid which which has the Rep and Cap functions and thus acts as a packaging plasmid to be introduced into the cell, and a plasmid which carries the gene of interest flanked by the AAV "terminal repeats".
  • This transfection is an infection by adenovirus layered, which provides the helper functions required for the replication of the AAV virus.
  • AAV is being used more and more as a vector system (Carter et al., 1992; Samulski et al., 1982; Kotin, 1994).
  • the most common method for the production of recombinant AAV is based on a two-plasmid system: the first plasmid codes for the Rep and Cap functions, a second plasmid codes for the gene of interest, which is less than 5000 bp in length must have, flanked by the 145 nucleotide long ITRs ("inverted terminal repeats").
  • the AAV Rep sequence effects the amplification of the gene sequence flanked by the ITRs, controlled by cis-acting signals in the ITRs.
  • the cap gene products then encapsulate the approximately 5000 nucleotide single-stranded genome, signals which are encoded by the ITRs also being used.
  • the progeny virus particles obtained with this method have no AAV genes and can infect a wide range of cell types and integrate them into their genome. It is these properties as well as the basic simplicity of producing new recombinant viruses that have made AAV popular for gene transfer applications.
  • Adenovirus vectors used in gene therapy have several methods (Ghosh-Choudhury et al., 1986; Bett et al., 1994; review by Berkner, 1992). These are based on the fact that infectious adenovirus can be formed following the transfection of adenovirus DNA (Graham and Van der Eb, 1973). One of these methods involves the co-transfection of two plasmids that can recombine with one another. One plasmid codes for the entire adenovirus genome, with the exception of one of the early virus genes (for example El), the sequence of which has been removed to make room for the insertion of a foreign gene.
  • El early virus genes
  • a second plasmid carries sequences immediately upstream and downstream of the location in the virus genome that was removed from the first plasmid. These areas are therefore present in both plasmids and can recombine with one another. If a foreign gene with a corresponding promoter is inserted between the second plasmid flanking areas complementary to the adenoplasmid, a subsequent recombination of the two plasmids leads to the uptake of the foreign gene into the viral genome.
  • the viral packaging signal Psi is removed from this plasmid and / or bacterial sequences are inserted which make the virus DNA too long for packaging and only by recombination with the second Plasmid to be removed.
  • the two plasmids are introduced into cells of a cell line which carries the adenovirus E1 sequence and thus has the function required for virus replication which the two plasmids lack.
  • Recombination of the two plasmids results in a DNA sequence which contains all functions for the replication and packaging of adenovirus, apart from the E1 functions which are provided by the cell line ("helper cells” or “production cells”), also that new gene encoded by the first plasmid (vector plasmid).
  • the standard method for producing this class of recombinant adenoviruses has been based on calcium phosphate transfection of the two plasmids in 293 cells. Following the transfection, the cells are overlaid with an agar layer. After an incubation period of 10 to 14 days, the adenovirus-infected cells become visible as plaques. During this time there is a recombination between the two plasmids. The plaques are formed by lysis of an originally infected cell and infection of the neighboring cells by the released virus, the top agar layer focusing and localizing the virus infection and allowing a virus to be isolated from a individual infection or recombination event. This plaque formation is often the limiting step in the production of recombinant adenovirus due to the low transfection efficiency that can be achieved with the calcium phosphate method and the low efficiency of plaque formation.
  • the object of the present invention was to provide an improved method for producing viruses and viral vectors.
  • Gene transfer in a physiological way, as represented by receptor-mediated endocytosis by means of nucleic acid complexes, has great advantages (non-toxic mechanism of passage through the cell membrane; possibility of administering biologically active nucleic acids, on a repetitive or continuous basis; possibility of cell-specific Targeting; producibility of the conjugates in large quantities).
  • An additional improvement of the system was achieved by a technique that uses the ability of certain viruses and virus components to break open endosomes. With the help of an addition this endosomolytic agents, a considerable increase in the expression rates of the genes imported into the cell could be achieved.
  • This method is essentially characterized by the transfer of large DNA fragments, the transfer in high number of copies and a mostly transient gene transfer.
  • the idea was considered to combine the advantages of the two gene transfer systems, namely the system based on recombinant viruses and the system based on receptor-mediated endocytosis, with the aim of achieving the high transfection efficiency of the system on the basis of receptor-mediated endocytosis, which uses endosomolytic agents to increase heterologous gene expression, for the production of viruses and viral vectors.
  • the present invention thus relates to a method for producing viruses or viral vectors, characterized in that one or more plasmids, containing viral vector DNA and / or one or more sequences, coding for viral genes which affect the infectivity of the virus or increase the viral vector, complexed with a polycation, optionally conjugated to a ligand for the target cell and transfected mammalian cells with the complex in the presence of an endosomolytic agent.
  • the viral vector DNA is preferably recombinant, i.e. H. in addition to viral vector sequences, it contains one in the target cell to which the viral vectors, e.g. used in the context of gene therapy, DNA sequence to be expressed, e.g. a therapeutically effective gene. (In the event that wild-type virus vectors are produced, they are used primarily for the production of vaccines).
  • a preferred embodiment of the method according to the invention consists in the plasmid DNA in the form of a ternary complex on the one hand with a conjugate of a ligand for the target cell and a polycation, for example transferrin-polylysine, and on the other hand with a conjugate of an endosomolytic agent and a polycation, eg adenovirus polylysine to be transported into the cells.
  • the endosomolytic agent is an adenovirus, which is present in the form of a polylysine conjugate that can be complexed with the DNA and thus integrated in the complex.
  • an inactivated adenovirus for example by means of physicochemical methods, optionally in a mixture with non-inactivated adenovirus, which is bound to polylysine via a biotin-streptavidin bridge.
  • this method is used in which the endosomolytic agent adenovirus and the ligand Transferrin is referred to as "adenovirus-assisted transfer infection”.
  • the method enables great variability; in this regard, reference is made to the disclosure of WO 93/07283.
  • the present invention is used in particular in the context of gene therapy.
  • genes which can be used in the context of somatic gene therapy and which may be present as part of recombinant virus vector DNA in the context of the present invention are factor VIII (hemophilia A) (see, for example, Wood et al., 1984), factor IX ( Hemophilia B), (see e.g. Kurachi et al., 1982), adenosine deaminase (SCID), (see e.g. Valerio et al., 1984), ⁇ -1 antitrypsin (pulmonary emphysema), (see e.g. Ciliberto et al., 1985) or the "Cystic fibrosis transmembrane conductance regulator gene" (see, for example, Riordan et al., 1989). These examples are not limitative.
  • the plasmid DNA codes for a retrovirus vector (this DNA is hereinafter referred to as "retrovirus vector DNA").
  • the application of the method according to the invention to retrovirus vector DNA gave titers, the level of which could not be expected to this extent.
  • the retroviral titers in packaging and primary cells that can be achieved with the aid of the method according to the invention achieve extremely high values: Transfected cells surprisingly contain five to ten or more intact integrated copies of provirus, which results in the production of 30 to 100 times higher titers of infectious vector particles. This gives 30 to 100 times higher titers of infectious vector particles than in comparison with the calcium phosphate method or by means of retroviral infection.
  • a decisive advantage of the method according to the invention is also that the transfected cells are free from replication-competent helper virus or replicating adenovirus.
  • the high titers were achieved not only for transiently transfected cells, but also for stable clonal or pooled transfectants.
  • the virus titer of pooled populations or transfected clones was not significantly lower than that of isolated clones, which is generally not the case with calcium phosphate transfected clones.
  • the increased virus titers were most likely due to multiple integrated copies of the transfected plasmids.
  • Infection of target cells eg NIH3T3
  • virus obtained from cells transfected with transferrin-polylysine / adenovirus was indistinguishable from infection with viruses derived from cells transfected with calcium phosphate.
  • retrovirus vectors there are no restrictions on the retrovirus vectors that can be used, a large number of which are available; all retroviral vectors are possible which have at least two LTRs and a packaging signal, that is to say the ice functions.
  • the trans functions, which represent the packaging functions, are optionally part of the retroviral sequence on a single plasmid or, in a preferred embodiment, in particular for therapeutic applications, they are on a separate plasmid, a so-called "packaging plasmid" (in this case the retrovirus vector DNA thus consists of two plasmids).
  • retrovirus vectors There is a great deal of literature on retrovirus vectors, packaging lines and their use in gene therapy applications. * Examples of suitable retrovirus vectors and the mechanisms of transduction of retroviruses are described, among others. in the reviews by Miller and Rosman, 1989, Morgenstern and Land, 1990, and Swain and Coffin, 1992.
  • Packaging plasmids contain sequences that code for retroviral proteins but do not carry retroviral regulatory units, thereby avoiding the formation of replication-competent helper viruses. Examples of packaging plasmids suitable in the context of the present invention have been described, inter alia, by Markowitz, 1988. 13
  • the method according to the invention is suitable for the rapid and simple production of stable cell lines which produce high titer of recombinant virus. In contrast to the methods according to the prior art, it does not require laborious transfection, subsequent infection and isolation of clones. A major advantage of the method is also that it can transiently produce recombinant viruses that are poorly tolerated by the packaging cell lines.
  • the method can preferably be used to generate viral vectors, e.g. produce retroviral vectors, also in non-packaging cells.
  • the embodiment of the invention is used for this, in which "packaging plasmids" are co-transfected with the vector DNA containing the other virus sequences.
  • the virus vector DNA consists of two plasmids, one of which contains the sequences coding for the packaging functions and one for the other virus proteins and the DNA to be expressed in the cell.
  • the advantage of the method according to the invention is particularly evident that the plasmids can be transported together into the cell after they have been mixed as a mixture in a defined quantitative ratio, preferably 3: 1 to 1: 3, were complexed with the other transfection components, for example with polylysine transferrin and with adenovirus-polylysine conjugates.
  • a vector plasmid or a retrovirus vector plasmid which carries the sequence to be expressed, in particular gene therapy, and a packaging plasmid can thus be brought into the cell in a coordinated manner be, the ratio varies and can be optimized with regard to the desired expression efficiency.
  • the optimal quantity ratio is determined using empirical tests.
  • retroviruses are rapidly broken down in the organism and thus often do not reach the target cells. Efficient gene transfer can therefore only be achieved with the retroviral vectors produced by conventional methods if they are applied directly to the target organ or even perfusion of the organ concerned, e.g. the liver. This effort can be avoided if supernatants with a high retrovirus titer are used for the transfection, which were produced by the method according to the invention in vitro (using packaging cell lines or, in the case of cells without a packaging function, by means of co-transfection of vectors containing packaging functions) .
  • Cells for example fibroblasts, haematopoietic cells, myoblasts, hepatocytes or bone marrow stromal cells, are removed from the organism and these primary Cells were transfected ex vivo with recombinant retrovirus vector DNA using the method according to the invention.
  • the vector-producing cells obtained in this way are then transplanted back into the organism in order to produce a large amount of vector material at the implantation site over a longer period of time, which leads to an in situ transduction of proliferating cells in the area.
  • the main advantage of such an application is that the continuous production of the vector in situ enables the transduction of cells with low division rates, such as stem cells and cells that contribute to the physiological cell turnover.
  • the transduction of the target cells with the retrovirus vector is carried out directly in vivo by locally applying transfection complexes according to the invention containing recombinant retrovirus vector DNA.
  • Terminally differentiated target cells such as blood cells, bronchial or intestinal epithelial cells, keratinocytes or mammary gland cells can thus be reached.
  • An example of a local in vivo application is the direct injection of the gene transfer complexes into the liver parenchyma or into the bile duct system with the aim of bringing the retroviral vectors and packaging plasmids into the bile duct epithelium in order to achieve in situ gene transfer into precursor cells.
  • Another example of a gene therapy application of the complexes according to the invention is the introduction of the human ⁇ -interferon gene into the mammary gland, whereby a direct in vivo transduction into the mammary gland epithelium can take place.
  • the plasmid contains DNA AAV vector DNA; the method according to the invention in this embodiment thus serves to produce recombinant AAV vectors.
  • the AAV sequences are preferably in the form of the two-plasmid system described above, in which a first plasmid for the rep and cap functions and a second plasmid for the gene of interest, flanked by the 145 nucleotide long ITRs ("inverted terminal repeats ").
  • AAV AAV genome-specific antibody
  • helper virus such as adenovirus or herpes virus.
  • adenovirus or herpes virus a helper virus
  • the system has another peculiarity which makes it particularly suitable for this application, namely the possibility of using inactivated adenovirus without impairing the functions required for the virus to enter this cell (Cotten et al., 1992; Cotten et al., 1994b).
  • a concentration of adenovirus particles can be used at a level which is sufficient for efficient gene transfer without the cell being overloaded with replication-competent adenovirus, which would compete with AAV for essential factors and thus reduce AAV production.
  • the method according to the invention offers for the embodiment in which the endosomolytically effective Adenovirus is also the helper virus for AAV, the possibility of using a mixture of active and inactive adenovirus particles, which allows the transfection system to be adapted in order to optimize AAV production.
  • the optimal ratio of inactivated and non-inactivated adenovirus can be determined empirically; it is generally desirable to keep the proportion of non-inactivated virus as low as possible. In the context of the present invention, ratios of inactivated: non-inactivated adenovirus of 4: 1 and 9: 1 have been found to be equally suitable.
  • the method according to the invention can be used to produce AAV particles without a helper virus infection taking place at the same time. Since only four gene functions of the adenovirus helper virus are required for AAV replication, namely El, E2a, E4 and VA (Richardson and Westphal, 1981), instead of using complete active adenovirus as helper virus, these helper functions are available in the form of plasmids each of which carries the relevant adenovirus gene regions. In addition, the helper functions, provided they are not present on the plasmid, can be provided by the production cells (the helper cells). These plasmids are co-transfected with the plasmids carrying the AAV sequences as part of the transfection complexes.
  • an endosomolytically active agent which is free from non-inactivated adenovirus can be used.
  • a single DNA molecule which contains the sequence coding for a non-packable adenovirus genome can be used for the co-transfection of the cells (in addition to the AAV sequences).
  • An example of such a plasmid is pBHGll (Bett et al., 1994), which contains the complete adenovirus genome with the exception of deletions of the E3 and the El region.
  • the plasmid pBHGll also has a deletion that removes the packaging signal Psi; in addition, the sequence encoded by it is too large for efficient adenovirus packaging.
  • the main advantage of this embodiment of the invention is the lack of production of the helper virus.
  • the plasmid DNA contains adenovirus vector DNA; in this embodiment the method is for the production of adenovirus and adenovirus vectors.
  • adenoviral vectors In a special variant of this embodiment for producing adenoviral vectors, two are inserted into the Plasmids containing adenovirus DNA sequences to be imported are selected such that the sequences can recombine. With the aid of the method according to the invention, it is possible to introduce the two plasmids into the cell in such large quantities that the formation of recombinant adenovirus is facilitated.
  • the first plasmid contains, for example, the ITR (Aleström et al., 1982) and the adenovirus packaging signals (base pairs 194 to 358; Gräble and Hearing, 1992) with a strong promoter that drives the foreign gene, plus an additional region of the adenovirus sequence, from which the El sequences were removed, it contains pIX sequences plus further sequences downstream from El, which enable recombination with the second plasmid.
  • the El region was removed from this vector system (plasmid) to make room for the insertion of foreign genes.
  • the second plasmid carries the entire adenovirus genome, from which the packaging signal has been removed and to which bacterial sequences have been inserted into the El region.
  • the two plasmids are introduced into cells of line 293 (Graham et al., 1977), a human embryonic kidney cell line which carries the adenovirus El sequence and thus has the function required for virus replication which the two plasmids lack. Recombination of the two plasmids results in a DNA sequence that contains all the functions that are required for the growth of adenovirus and the DNA packaging (apart from the E1 functions provided by the cell line), as well as the new gene, the is encoded by the first plasmid.
  • an E4 cell line for example the cell line W162, or an E1 / E4 cell line which has both gene functions can be used; in this case the adenovirus vector DNA plasmids lack the E4 function or both EI and E4 function.
  • the method according to the invention is used to produce recombinant adenoviruses which can penetrate the cell and carry a foreign DNA molecule of 35 kb, but which are completely lacking adenovirus genes.
  • adenoviruses the following plasmid constructs can be used, for example: a first plasmid (vector plasmid) contains the ITRs of adenovirus and the packaging signal Psi, which contains the approx.
  • a second plasmid contains the complete adenovirus sequence but lacks the Psi packaging function and an insert size of more than 35 kb prevents its packaging. Examples of plasmids suitable for the purposes of the present invention are those described by Bett et al. , 1994, described plasmid pBHGll, which is El-negative, and structurally similar plasmids.
  • El-positive plasmids can be used, in which case the use of a production or helper cell is not necessary, normal cells can be used for the transfection.
  • the second plasmid (packaging plasmid) provides all the gene functions which are necessary for the education of an infectious adenovirus particle are required, which assembles and is loaded with the sequence encoded by the first plasmid. This system has the advantage of delivering infectious adenovirus particles that do not have adenovirus genes because the two plasmids do not recombine with one another.
  • This embodiment of the present invention with which large amounts of both plasmids are transported into the packaging cell line by means of a transient transfection, avoids the problem of requiring cell lines which stably carry large portions of the adenovirus genome, which has proven to be difficult, presumably because of the toxic effects of some adenovirus products.
  • Another advantage of this "defused" adenovirus vector is the increased capacity for foreign genes. While the recombinant adenovirus vectors of the prior art can take up approximately 8 kb of a foreign sequence, the vector obtainable with the method according to the invention, which only requires the approximately 200 bp ITR sequences plus a 180 bp packaging sequence, can contain more than 34 kb of foreign genes how to absorb therapeutically effective genes.
  • Another advantage of this embodiment of the invention lies in its great flexibility, because the adenovirus genes can be distributed over different plasmids (vector plasmid, packaging plasmid and optionally further plasmids). Deviating from the embodiment in which the vector plasmid carries only the packaging function psi in addition to the foreign gene and the ITRs and the packaging plasmid carries the remaining adenovirus sequences, some of these adenovirus sequences can also be present on the vector plasmid, while the remaining functions are entirely or only partially encoded by the packaging plasmid. In addition to the packaging plasmid and the vector plasmid, these functions can also be provided by the cell and / or can be present on another plasmid.
  • the method according to the invention can also be used to produce adenoviruses or adenoviral vectors which have changes or additions to different gene functions in order to improve the infectivity of the virus.
  • adenoviruses or adenoviral vectors which have changes or additions to different gene functions in order to improve the infectivity of the virus.
  • the manipulated or complementary genes in trans are used to produce recombinant or non-recombinant adenoviruses (in accordance with the principle proposed, for example, for the E1 sequence by Goldsmith, et. Al. 1994, these genes) but also, when using the multi-plasmid system for producing adenoviral vectors, on which packaging or the vector plasmid can be present.
  • An example of such a manipulation is the targeted modification of the fibers of an adenovirus in order to bind to specific types of target cells;
  • the basis for this is the possibility of being able to exchange the fiber genes between different adenovirus serotypes.
  • a manipulated fiber gene e.g. on the packaging plasmid or on a separate plasmid, allows the production of
  • Adenovirus particles that have new fiber molecules and are therefore suitable for alternative applications with regard to specific target cells.
  • the adenovirus or the adenovirus vector can also be changed in order to overexpress To induce adenovirus protease, so in this case the viral gene that increases infectivity is the protease gene.
  • the adenovirus protease is required for processing six of the capsid proteins when assembling the virus; the specific cleavage of the viral capsid proteins activates the adenovirus particle for interaction with the membrane.
  • the protease is required for DNA to enter the nucleus, both adenovirus DNA and DNA coupled to the surface of adenovirus in adenovirus-assisted transfer infection.
  • protease it is possible to provide larger amounts of protease during productive adenovirus infection.
  • the presence of additional protease during the production of the virus has two advantages: the increased amount ensures that all virions obtained are completely processed and have full activity for breaking the membranes.
  • the higher amount of protease can also result in the additional protease being encapsulated in larger amounts in the virions obtained. As a result, these virions can be more efficient in the reactions that take place when DNA is transferred into the nucleus of the infected cells.
  • the, optionally recombinant, adenovirus is used to form complexes with polylysine, and optionally a conjugate of a ligand and polylysine, and DNA, which contains the sequence coding for the protease .
  • the complexes obtained trigger a productive virus infection; the protease gene contained on the plasmid ensures, compared to the amount, which is achieved by the genomic copy of the gene, an excess of the protease virion (under normal conditions there are approximately 10 protease copies per virion).
  • the advantage of this embodiment is that the virus genome is separate from the modified protease gene (the modification consists in the presence of a strong constitutive promoter).
  • adenovirus particles which differ from normal infection only in their increased protease content and the increased processing of the virion.
  • adenoviruses can be used, for example, to produce tumor vaccines by the method described in WO 94/21808, in order to introduce a cytokine gene into tumor cells.
  • a recombinant virus can be produced which carries the protease gene under the control of a strong constitutive promoter.
  • the two- or multi-plasmid system is used, and the protease gene can be contained on the vector plasmid, optionally in addition to the foreign gene, for example a therapeutically active gene such as a cytokine gene.
  • the protease gene can be contained on the packaging plasmid or on a third plasmid).
  • protease plays a role in the inflammatory response to the occurrence of adenovirus; increasing the protease content of adenovirions can increase the inflammatory potential of the virus. While this can be a disadvantage in the production of long-term modified cells for certain applications, this property is an advantage in the production of tumor vaccines with which an increase in the immune response of the organism is to be achieved.
  • adenovirus vectors
  • YAC yeast Artificial Chromosome
  • This system uses the efficient homologous recombination reactions in yeast to introduce the desired changes in the adenovirus genome.
  • the adenovirus sequence is cut out of the YAC and inserted into a cell line suitable for the growth of adenovirus.
  • this system has the disadvantage that the transfection of the large adenovirus sequence (35 kb) with the calcium phosphate transfection method is inefficient and therefore the transfection is the limiting step in this method.
  • This disadvantage can be eliminated by using the method according to the invention to deal with the YAC system to manipulate manipulated adenovirus vector sequences, which enables rapid adenovirus infection to be triggered.
  • helper cells which contribute the helper functions missing from the AAV or adenovirus vector plasmids
  • these helper functions can also be contained on another plasmid, which is transfected together with the remaining vector DNA contained on plasmids.
  • the target cells in which the foreign DNA, e.g. B. the therapeutically effective DNA is ultimately brought to expression, transfected the production of the vector in these cases does not take place in the helper, but directly in the target cell.
  • the present invention relates to transfection complexes containing DNA in the form of one or more plasmids, containing viral vector DNA and / or one or more sequences, coding for viral genes which increase the infectivity of the virus or the viral vector complexed with a polycation, optionally conjugated to a ligand for the target cell, and an endosomolytic agent.
  • the plasmid DNA is retroviral vector DNA.
  • the plasmid DNA is AAV vector DNA.
  • the endosomolytic agent consists of a mixture of inactivated and non- inactivated adenovirus, the latter also acting as a helper virus for the AAV.
  • the plasmid DNA is adenovirus vector DNA.
  • the plasmid DNA codes for adenovirus protease; in this case the endosomolytic agent, possibly recombinant, is adenovirus.
  • Fig. 1 Flow cytometry analysis of the HERc
  • Expression Fig. 2 Analysis of genomic DNA to determine the
  • FIG. 3 Western blot for the detection of AAV virus
  • Fig. 4 Production of adenovirus with increased
  • Mouse hepatocytes BNL CL.2 (ATCC No. TIB 73); Packing cell line GP + E86 cells described by Markowitz et al., 1988, NIH3T3 (TK-) cells.
  • the retroviral vectors expressing the normal human EGF receptor (HERc), c-kit or tsp53 were derived from the vector LXSN described by Miller and Rosman, 1989.
  • the plasmid LXSN-HERc was prepared by inserting a 3.9 kb Xhol fragment obtained from the plasmid NTK-HERc (von Rüden and Wagner, 1988) into the Xhol site of pLXSN.
  • the LXSN-tsp53 virus was obtained by inserting the cDNA coding for the p53vall35 mutant (Gott Kunststoff et al., 1993) into the EcoRI site of pLXSN.
  • the vector pLXSN kit was developed by Alexander et al. , 1991, described; the plasmid pLSXN-tsb53 was developed by Gottling et al. , 1993.
  • the plasmid pMOV9.2 was described by Harbers et al., 1981.
  • the titer of the recombinant viruses were determined by infecting NIH3T3 (TK-) cells (10 5 cells per 6 cm dish for 2 h and then selecting with G418 (Gibco, 1 mg / ml), the medium being IMDM (Iscoves modified Dulbeccos medium (Gibco) and 10% FCS was used.
  • adenovirus transfer infection Polylysine / adenovirus-DNA complexes (hereinafter referred to as "adenovirus transfer infection”) was carried out essentially as described in WO 93/07283.
  • the individual procedure was as follows: the transfection complexes were produced in a three-stage process.
  • 8 x 10 9 particles of biotinylated, psoralen / UV-inactivated adenovirus dl312 were modified with streptavidin-modified polylysine 290 by adding in a total volume of 200 ⁇ l HBS (20 mM HEPES, 150 mM NaCl, pH 7.4) for 30 min Was incubated at room temperature.
  • the complexes were treated with 1.5 ml of culture medium (for GP + E86 cells: IMDM, containing 5% FCS, 50 ⁇ M ⁇ -mercaptoethanol and antibiotics; for the mouse hepatocytes BNL CL.2: high-glucose DMEM, containing FCS and antibiotics) diluted and allowed to act on 3 x 10 5 cells per 6 cm culture dish for 4 hours at 37 ° C. The medium was then replaced by fresh culture medium. 48 h after the transfection, the supernatants were examined for the formation of recombinant retroviruses.
  • culture medium for GP + E86 cells: IMDM, containing 5% FCS, 50 ⁇ M ⁇ -mercaptoethanol and antibiotics; for the mouse hepatocytes BNL CL.2: high-glucose DMEM, containing FCS and antibiotics
  • the cells were washed twice with phosphate buffered saline (PBS) supplemented with FCS and 0.05% sodium azide (wash buffer) before being blended for 30 min with the monoclonal antibody R1 (Waterfield et al., 1982), which is the extracellular domain of human EGF -Receptor detects were incubated.
  • Fluorescein was labeled as a secondary antibody F (from 1 ) 2 fragments of goat anti-mouse IgG (Dianova) used.
  • the living cells were analyzed using a Becton-Dickinson FACScan analyzer.
  • NIH3T3 (TK-) fibroblasts were infected according to standard protocols and selected for the expression of the transduced Neo R gene: 1 ⁇ 10 5 NIH3T3 were incubated with 1 ml of supernatant from culture-producing cells for 1 to 2 h. The supernatants were previously diluted in culture medium (IMDM + 10% FCS). After the infection, the virus-containing medium was exchanged for virus-free medium and the cells were then cultivated for 24 to 30 h. G418 (1 mg / ml) was then added to the medium for selection of the infected cells.
  • Genomic DNA was prepared from 3 ⁇ 10 6 cells (Sambrook et al., 1989) and digested 10 ⁇ g with the appropriate endonucleases. The cut DNA was separated on agarose gels and then applied to nylon membranes. The blots were hybridized with 32 P-labeled cDNA probes. To determine the intact integration of provirus, the DNA was cleaved with Asp718, which cuts once within the proviral LTRs, whereby a diagnostic DNA fragment is released. Digestion with Hindlll, which cuts once in the provirus genome, provides Restriction fragments that are characteristic of each integration site. The blots were analyzed with a neo-specific probe.
  • Adenovirus 5 dll014 (Bridge and Ketner, 1989) was grown in W162 cells (Weinberg and Ketner, 1983).
  • Ad5 wt300 wild type adenovirus type 5
  • Ad5 dl312 adenovirus with a deletion in the Ela region; Jones and Shenk, 1979
  • Viruses were purified, where indicated, biotinylated and, where indicated, inactivated with psoralen / UV as described by Cotten et al. , 1994b.
  • All plasmid DNA was purified using Qiagen chromatography (Diagen GmbH) followed by Triton X-114 extraction to remove LPS (Cotten et al., 1994a).
  • Streptavidin polylysine was prepared according to the method described by Wagner et al. , 1992, transferrin polylysine according to the method described by Wagner et al. , 1991, obtained method, these methods are also described in WO 93/07283.
  • the transfection complexes were obtained as follows: a sample of biotinylated adenovirus with 1 ⁇ 10 10 particles was diluted in 150 ⁇ l HBS and with 1 ⁇ g streptavidin-polylysine in 150 ⁇ l HBS mixed for 30 min at room temperature.
  • the preliminary experiments were carried out with the wild-type AAV-2 vector pAV-1 (Laughlin et al., 1983; available from ATCC).
  • the subsequent attempts to produce recombinant AAV vectors were performed using the AAV vector pAB-11 (pAAVLACZ; Kaplitt et al., 1994), which contains the sequence coding for ⁇ -galactosidase, and the plasmid pAd8 (Kaplitt et al., 1994).
  • the original pAB-11 preparations were recloned; a clone that had retained the second terminal repeat was isolated and expanded for reuse.
  • the adenovirus 5 plasmid lacking the El sequence, the plasmid p ⁇ ElsplB (left end) and the packaging plasmid pBGHll (right end) were obtained from Microbix.
  • the supernatant was then transferred to a vertical centrifuge tube (either vTi 50 for volumes from 10 to 15 ml, or vTi 65 for volumes from 2 to 5 ml) with an equal volume of 1.33 g / cm 3 CsCl, 20 mM HEPES, pH 4, followed by half a volume of 1.64 g / cm 3 CsCl, 20 mM HEPES, pH 4.
  • the material was then centrifuged for 2 hours at 49,000 rpm (vTi 50) or 63,000 rpm (vTi 65) at 20 ° C.
  • the gradient fractions were harvested as follows: the clearly visible opalescent adenovirus band midway through the 1.33 g / cm 3 CsCl level was harvested, followed by a second fraction spanning the region from adenovirus to 1.64 g / cm 3 CsCl level .
  • This second fraction containing the AAV, was mixed with 1.40 g / cm 3 CsCl, 20 mM HEPES, pH 7.4 and centrifuged overnight in a vTi 65 rotor.
  • Luciferase activity was determined using standard methods, such as described in WO 93/07283.
  • ECL Enhanced Chemiluminescence
  • the DNA coding for the retroviral vector pLXSN-HERc was transfected into cells of the packaging cell line GP + E86, on the one hand by means of calcium phosphate coprecipitation method, on the other hand by means of adenovirus transfer infection.
  • the release of the infectious LXSN-HERc was determined 24 and 28 h after the transfection or after selection for G418 for one week.
  • the results are shown in Table I: as expected, only small virus titers (in the range of 10 3 infectious units per ml (cfu / ml)) could be detected in the cells transiently transfected with calcium phosphate. In the pooled population of G418-resistant clones, the titers rose significantly to approx.
  • FIG. 1A shows the expression of human EGF-R (HERc) on the surface of transfected clonal GP + E86 cells after G418 selection.
  • Figure 1B shows the expression of HERc on infected NIH3T3 TK cells.
  • plasmid pMOV9.2 which contains a complete Molony mouse leukemia virus (M-MuLV) was used for this.
  • M-MuLV Molony mouse leukemia virus
  • the vector LXSN kit expresses the receptor encoded by c-kit
  • the second construct LXSN-tsp53 expresses a temperature-sensitive mutant of the tumor suppressor gene p53.
  • Table IV the virus titers of the adenovirus transfer infection-transfected cells were uniformly 40 to 100 times higher than those in cells which had been transfected with calcium phosphate.
  • the plasmid pLXSN-HERc was co-transfected together with the plasmid pMOV9.2 (3 ⁇ g each) in BML CL.2 hepatocytes.
  • Table V shows, approximately 50% of the clones isolated gave a virus titer which was almost as high as that of the GP + E86 producer cells and showed high expression values for HERc on the cell surface. Since a full-length M-MuLV virus was co-transfected in this experiment, these cells also released replication-competent helper virus.
  • genomic DNA analysis was performed (Sambrook) to determine whether the transfected plasmid had been integrated into the host cell genome and whether the number of integrated plasmid copies correlated with the increase in titer.
  • Southern blot analysis of the DNA from cells transfected by adenovirus transfer infection showed at least two and up to more than ten integration sites, while those with calcium phosphate transfected clones generally contained only one or two copies (Fig. 2A). The number of integrated copies correlated well with the virus titers (see Table IV).
  • the number of integrated plasmids was generally lower in comparison to the GP + E86 cells, but also correlated with the virus titers. Restriction digestion of the genomic DNA with an enzyme that cuts once in the LTRs confirmed the integrity of the integrated retroviral construct. Only one BNL CL.2 clone (# 6) containing more than ten integrated copies had two rearranged vectors ( Figure 2B). Finally, the blots were rehybridized with adenovirus-specific probes to determine whether adenovirus sequences had also been integrated into the genome of the cells that had been transfected by adenovirus transfer infection.
  • FIG. 2A shows Southern analysis of genomic DNA from cells transfected with the plasmids shown in the figure. HindIII, which cuts the proviral DNA once and thus provides fragments which are characteristic of a single integration site, was used as the restriction enzyme (FIG. 2C).
  • FIG. 2B shows the analysis of transfected BNL CL.2 cells, cut either with Hindill or with Asp718, which cuts once in each proviral LTR and thus provides fragments which are an indication of the integrity of the proviral integration (FIG. 2C).
  • vector-specific DNA was detected by hybridization with a 32 P-labeled neo-probe.
  • a CPE assay also showed that replicating adenovirus, which could have developed from non-integrated adenovirus DNA, was not detectable in retroviral supernatants.
  • the plasmid pAVl encoding the entire human wild-type AAV type 2 (Laughlin et al., 1983), was transformed using transfection complexes containing a mixture of biotinylated Ad5 dll014 and biotinylated psoralen / UV-inactivated Ad5 dll014 (1: 9 and 1: 4; the transfections of the two parallel experiments in both quantitative ratios brought the same positive result) transfected in W162 cells. 3 days after the transfection (as soon as almost all cells had rounded and detached from the surface), the cells were harvested, suspended in 20 mM HEPES, pH 7.4, lysed by means of three freeze / thaw cycles and extracted with an equal volume of freon.
  • the lysate was then fractionated on a CsCl step gradient using 15 ml of lysate with 15 ml of 1.33 g / cm 3 CsCl, 20 mM HEPES, pH 7.4 and then with 7 ml of 1.64 g / cm 3 CsCl, 20 mM HEPES, pH 7.4 , was layered in a vTi 50 tube. The sample was then centrifuged at 49,000 rpm for 2 hours. A fraction was harvested that contained the distinct, opalescent band midway through the 1.33 g / cm 3 step plus the higher density material.
  • the sample was adjusted to 1.40 g / cm 3 with CsCl / 20 mM HEPES, pH 7.4 and centrifuged overnight in a vTi 65 rotor at 63,000 rpm for 18 h. It was isolated a single sample with a density of 1.35 g / cm 3 .
  • the presence of AAV was determined by dissolving the fractions by SDS-PAGE, transferring to nitrocellulose and contacting an antibody that recognizes the AAV capsid proteins VP-1, VP-2 and VP-3 (Ruffing et al., 1992; ProGen, Heidelberg). The expected AAV fractions were found to contain proteins of the expected size.
  • the Western blot is shown in Fig. 3; lanes 1 to 3 show the reaction of the AAV proteins VP1, VP2 and VP3 with the antibody; the molecular weights are shown on the left in the figure.
  • the plasmids pAB-11 and the plasmid pAD8, which were transfected together in a ratio of 1: 1 in W162 cells, in order to obtain recombinant AAV vectors, were analogous to those in a).
  • HeLa cells were infected with the recombinant AAV virus obtained and the ⁇ -galactosidase production in the cells was confirmed.
  • the reporter gene luciferase was used under the control of the CMV promoter to produce an El-defective adenovirus.
  • a plasmid was first prepared which contained the left ITR, the packaging function Psi, the sequence coding for luciferase under the control of the CMV promoter (including the cleavage site and polyA tail) by the sequence coding for luciferase (De Wet et al.
  • the plasmid obtained was then co-transfected with a second plasmid pBHGll (Bett et al., 1994) which codes for the entire Ad5 genome, with the exception of a deletion in the E3 region, a deletion in the El region Deletion of the packaging signal Psi, which contains a bacterial plasmid insert in the El region, which makes the complete sequence too large for packaging into a virion.
  • pBHGll Bett et al., 1994
  • Adenovirus 5 dll014 was grown as described in the method section.
  • Adenovirus Ad2tsl (temperature sensitive to the adenovirus protease, * Weber, 1976; Yeh-Kai et al., 1983) was grown at 32 ° C on W162 cells. At this temperature, the virus produces particles that have the capsids and infectivity of the wild type (Weber, 1976; Yeh-Kai et al., 1983).
  • the infected cells were lysed using three freeze / thaw cycles, with freon extracted and using a CsCl gradient (first step gradient cleaning followed by equilibrium centrifugation in CsCl) as described by Cotten et al. , 1994, described, cleaned.
  • the purified virus (0.3 to 1 mg / ml protein, corresponding to 1 - 3.4 x 10 12 virus particles per ml) was biotinylated with NHS-LC-Biotin (Wagner et al., 1992) and dialysed extensively against HBS / 40% glycerol.
  • Ad5 dll014 wild-type protease gene
  • Ad2 tsl temperature-sensitive protease
  • virus samples (10 10 virus particles) were diluted in 150 ⁇ l HBS and mixed with 1 ⁇ g streptavidin-polylysine in 150 mM HBS. After 30 min at room temperature, 6 ⁇ g DNA (either pSP65 (Boehringer Mannheim) or pPCR gap # 9) in 100 ⁇ l HBS were added, after a further 30 min 4 ⁇ g transferrin-polylysine in 100 ⁇ l HBS.
  • the transfection complexes were placed on the W162 cells (8 ⁇ 10 6 cells in a 180 cm 2 bottle) in 10 ml of 2% horse serum / DMEM. After 2 hours at 37 ° C the medium was replaced with 10% FCS / DMEM and the cells were exposed to a temperature of 39 ° C. After 3 days, when the complete cytopathic effect was observed, the cells were harvested, the adenovirus obtained was purified and the virus was quantified via the protein content.
  • TfpL / DNA complexes containing 6 ⁇ g pCLuc / 6 ⁇ g TfpL prepared in 500 ⁇ l HBS. Aliquots of 25 ⁇ l were applied to HeLa cells (40,000 cells per well of a 24-well plate in 500 ⁇ l horse serum / DMEM), followed by 10,000 adenovirus particles, which were either infected with Ad5 dll014 / pSP65, with Ad5 dll014 / pPCRSpalt # 9, with Ad2 tsl / pSP65 or with Ad2 tsl / pPCRSpalt # 9.
  • Fig. 4 It was found that Ad2 tsl particles, when coupled with an empty DNA plasmid, produce virus at 39 ° C. which cannot increase the transfer of luciferase DNA (FIG. 4, column 1). In contrast, the coupling of the plasmid pPCRSpalt # 9, which carries the wild-type protease gene, increased the luciferase activity; this shows that the wild-type protease gene, which is transported into the cell with a plasmid coupled to the virus, can replace the defective gene in the virus genome.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procédé de préparation de virus et de vecteurs viraux par transfection de cellules de mammifères avec des complexes d'ADN viral et d'un polycation qui, éventuellement, est conjugué avec un ligand pour la cellule cible, en présence d'un agent endosomolytique. Le procédé offre des avantages particuliers pour la production de rétrovirus de recombinaison, d'adénovirus et de virus adéno-associés dans la cellule, ce qui permet d'obtenir des titres élevés en virus dans des lignées cellulaires d'encapsidation ainsi que dans des cellules primaires. Le domaine d'application concerne principalement la thérapie génique.
EP95926867A 1994-07-26 1995-07-13 Procede de preparation de virus et de vecteurs viraux Withdrawn EP0774009A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4426429A DE4426429A1 (de) 1994-07-26 1994-07-26 Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
DE4426429 1994-07-26
PCT/EP1995/002737 WO1996003517A1 (fr) 1994-07-26 1995-07-13 Procede de preparation de virus et de vecteurs viraux

Publications (1)

Publication Number Publication Date
EP0774009A1 true EP0774009A1 (fr) 1997-05-21

Family

ID=6524166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95926867A Withdrawn EP0774009A1 (fr) 1994-07-26 1995-07-13 Procede de preparation de virus et de vecteurs viraux

Country Status (9)

Country Link
EP (1) EP0774009A1 (fr)
JP (1) JPH10502822A (fr)
AU (1) AU711296B2 (fr)
CA (1) CA2194465A1 (fr)
CO (1) CO4410256A1 (fr)
DE (1) DE4426429A1 (fr)
MX (1) MX9700555A (fr)
WO (1) WO1996003517A1 (fr)
ZA (1) ZA956164B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19615803A1 (de) 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO-Virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
IL103059A0 (en) * 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
CN1119459A (zh) * 1993-03-19 1996-03-27 柏伦格-英格尔海姆国际股份公司 肿瘤疫苗的制备方法
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9603517A1 *

Also Published As

Publication number Publication date
WO1996003517A1 (fr) 1996-02-08
JPH10502822A (ja) 1998-03-17
CA2194465A1 (fr) 1996-02-08
CO4410256A1 (es) 1997-01-09
AU711296B2 (en) 1999-10-07
AU3110295A (en) 1996-02-22
MX9700555A (es) 1997-05-31
DE4426429A1 (de) 1996-02-01
ZA956164B (en) 1997-02-25

Similar Documents

Publication Publication Date Title
DE69534166T2 (de) Rekombinanter adenovirus und methoden zu dessen verwendung
DE69518910T3 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
EP0606280B1 (fr) Nouveaux composes conjugues pour l'introduction d'acide nucleique dans des cellules eucariotes superieures
DE69633572T2 (de) Hilfsfunktionen fuer die rekombinante aav-virionherstellung
DE69633565T2 (de) Verpackungssysteme für humane rekombinante adenoviren, zur vewendung in der ge ntherapie
US7045344B2 (en) Adenoviral vector and methods for making and using the same
DE69634752T2 (de) Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element"
DE69535340T2 (de) Rekombinantes Adeno-assoziiertes Virus
DE60018920T2 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
DE69619110T2 (de) Adenovirale vektoren für die gentherapie
DE69425989T3 (de) Neue Komplementations-Zelllinien für defekte adenovirale Vektoren
DE60035124T2 (de) Ein oncolytisches adenovirus
DE69914382T2 (de) Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression
DE69634300T2 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
WO1995026411A2 (fr) Composition et methodes d'obtention de cellules productrices de virus de recombinaison isogeniques
JP4787440B2 (ja) 変異型ｆｒｔ配列を含有してなるｄｎａ
DE69828167T2 (de) Rekombinante adenovirale vektoren, die eine spleissequenz enthalten
DE69725882T2 (de) Adenovirus e4 proteine für induktion von zelltod
US5707865A (en) Retroviral vectors for expression in embryonic cells
EP0746624B1 (fr) Vecteur pour l'expression specifique du foie
WO1996003517A1 (fr) Procede de preparation de virus et de vecteurs viraux
EP1409700A2 (fr) Systeme destine a produire des populations clonales ou complexes d'adenovirus recombines et leur application
EP0263328A1 (fr) Vecteurs viraux spécifiques de tissus à base de LPV et leur utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

17Q First examination report despatched

Effective date: 20031203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040615